Lyell Immunopharma, Inc. (LYEL): M&A transaction — Lyell Immunopharma completes $30M+stock acquisition of ImmPACT Bio, gains CD19/20 CAR T candidate

Lyell Immunopharma, Inc.

Upfront: $30M cash (adjusted for ~$12M ImmPACT cash) plus 37.5M Lyell shares; contingent milestone shares up to 12.5M and low-single-digit royalty.
IMPT-314 (dual-targeting CD19/20 CAR T) expected to start pivotal trial in 2025 for third-line CAR-naïve B-cell non-Hodgkin lymphoma.
Sumant Ramachandra, former ImmPACT CEO, appointed to Lyell's Board of Directors.
Lyell expects cash to fund operations into 2027 through clinical milestones including pivotal trial initiation for IMPT-314.

item 1.01 item 2.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sumant Ramachandra

Class III director

LYEL · Lyell Immunopharma, Inc.

Effective: 2024-10-31
Filed: October 31, 2024, 7:59 PM ET

Sumant Ramachandra, M.D., Ph.D., who was the Chief Executive Officer and a director of ImmPACT prior to the consummation of the Merger, was appointed as a Class III director to the Board of Directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sumant Ramachandra was appointed as Class III director at Lyell Immunopharma, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

Sumant Ramachandra, M.D., Ph.D., who was the Chief Executive Officer and a director of ImmPACT prior to the consummation of the Merger, was appointed as a Class III director to the Board of Directors of the Company.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Lyell Immunopharma, Inc. completed an acquisition involving ImmPACT Bio USA Inc. for $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock (closed 2024-10-31).

Action: acquisition
Counterparty: ImmPACT Bio USA Inc.
Consideration: $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock
Closing: 2024-10-31

Exact text from the filing

Pursuant to the terms of the Merger Agreement, on the Closing Date, the Company acquired all of the outstanding equity interests of ImmPACT in exchange for an upfront payment of $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock. The acquisition was effected via a

View on SEC.gov

30 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-248760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.